Pharmaceuticals

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

Interim Phase 3 data shows Otsuka's VOYXACT not only meets surrogate endpoints but preserves kidney function, a strategic masterstroke in the competitive nephrology market.

Facing dire financial warnings, Cosmos Health plans to sell its own facilities to fund a comeback. Is it a stroke of genius or a desperate final gambit?

A blockbuster drug for chronic illness gets a generic rival, promising huge savings. But is it just about price? A deep dive into the strategy behind the new pill.

Australian biotech Gelteq is opening a China R&D hub to chase explosive growth, but its bold move into a $60B market comes with significant geopolitical risks.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

Scilex sets a date to pay out Semnur stock to its shareholders. We dig into whether this is a true value unlock or a move born from financial pressure.

New data showing a 300% spike in demand for Burmese prescription translations is a stark economic signal of a deeper demographic shift challenging U.S. healthcare.

As the deadly Bundibugyo Ebola strain spreads with no approved vaccine, a small pharma company is positioning its cancer drug as a potential broad-spectrum shield.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.

A key regulatory win in Japan propels a potential first-ever treatment for Netherton Syndrome, but the real story is the high-wire act of global commercialization.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

SciSparc's subsidiary just spent nearly C$10M on a quantum computing firm. This is the operational innovation designed to fix billion-dollar clinical trial failures.

With a 'best-in-class' obesity drug and a novel MASH therapy, clinical-stage MetaVia is set to woo investors. Can its science stand out against the giants?

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

A new collaborative funding model is accelerating a revolutionary approach to ALS treatment, targeting the disease's core mechanism. Here's the why behind the buy.